Figure 1.
Patient disposition. Patients who received placebo during the double‐blind period and open‐label sitagliptin in the open‐label period (P/S group). Patients who received sitagliptin in both periods (S/S group).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.